Merck reported a solid first quarter with maintained sales guidance despite an 8% YoY revenue decline, attributed to divestitures and foreign exchange impacts. Management emphasized strong pipeline developments, particularly with KEYTRUDA and expanding non-defense markets, which bolsters investor confidence. The positive outlook on future growth and strategic initiatives is likely to support a favorable short-term stock movement.

[1]